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1 Introduction
In pregnancies complicated by diabetes, maternal
and subsequent fetal hyperglycemia will lead to an
increased fetal secretion of insulin. The degree of
fetal hyperinsulinemia is reflected in the amniotic
fluid concentration of C-peptide, the connecting
peptide of proinsulin, which probably reaches the
amniotic fluid via the fetal urine. Several investiga-
tors have shown an association between elevated
levels of C-peptide in the amniotic fluid and
neonatal complications in diabetic pregnancies
[15,20].
Neonatal disorders such as respiratory disturb-
ances, hypoglycemia, hyperbilirubinemia and
feeding difficulties may reflect delayed functional
maturation of different organs. So far, only the
functional maturity of the lung can be assessed
prenatally, by determination of the lecithin/
sphingomyelin (L/S)-ratio, or lately by estimation
of other surfactant components in the amniotic
fluid [7]. Among these surf ace-active phospho-
lipids, phosphatidyl glycerol is considered to be
a reliable indicator of pulmonary maturity not
only in normal but also in diabetic pregnancies
[2,8]. ·
The aim of the present study was to assess the
possibility of a relationship between the level of
C-peptide and the presence of phosphatidyl
glycerol in the amniotic fluid, in strictly controlled
diabetic pregnancies.
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2 Materials and methods
Subjects
The study comprised a consecutive series of 36*
pregnant diabetic patients, classified as suggested
by WHITE [23]. Gestational diabetes was diag-
nosed by a 3 hour, 50 gram oral glucose tolerance
test as described earlier [6, 9]. Twenty-one of the
patients were insulin-treated gestational diabetic
women (White class AB) and 15 were insulin-
dependent diabetic women (12 of classes B—D
and 3 of class F). All patients were subjected to
a program of strict metabolic control during
their pregnancy [16]. Blood glucose levels were
monitored at home by the patients either by
means of reagent strips alone or by a reflecto-
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meter. The insulin dose was adjusted according to
the blood glucose values with the goal being to
keep the blood glucose within the physiological
range, i.e. between 3.0 and 6.5mmol/l.
Amniotic fluid investigations
Transabdominal amniocentesis was performed at
36-37 weeks of gestation as part of the routine
program for fetal surveillance in diabetic women.
The presence or absence of phosphatidyl glycerol
was assessed on centrifuged (1100 χ g; 5 minutes)
amniotic fluid samples, kept frozen and stored at
-20 °C until analysis. Phosphatidyl glycerol
was determined as described by HALLMAN and
TERAMO [8], by two-dimensional thin-layer chro-
matography. The phospholipids were stained by
iodine vapors and the presence of phosphatidyl
glycerol was recorded as an indicator of pulmo-
nary maturity [8]. The lower detection limit for
phosphatidyl glycerol in amniotic fluid was
0.33 Mg/ml.
C-peptide in the amniotic fluid was measured by
radioimmunoassay [10] after treating the samples
with polyethylene glycol to remove insulin-
binding, antibodies [11].
FlSHER's exact probability test and the MANN-
WHITNEY U test were used for statistical analyses;
p < 0.05 was considered as statistically significant.
3 Results
Amniocentesis was performed 2—3 weeks before
delivery in women of White Class AB and B—D
(Tab. I). All diabetic patients were delivered at
term with the exception of 3 patients of White
class F, who were delivered preterm because of
pregnancy complications. The concentration of
C-peptide in the amniotic fluid did not differ
between White classes AB and B-D at the time of
amniocentesis. Phosphatidyl glycerol was present
in 9 of 21 patients of White class AB as compared
with 6 of 12 in White class B-D. It was not
present in any patient of class F, and in this class
the concentration of C-peptide in the amniotic
fluid was lower than in patients of classes B—D.
A correlation was found between the concentra-
tion of C-peptide in the amniotic fluid and the
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The relationship between the amniotic fluid concentration
of C-peptide and the infants' birth weights.
Tab. I. Mean values ± 2 SEM for the gestational week of amniocentesis and of delivery, birth weight, and concentration
of C-peptide in the amniotic fluid, and the proportion of cases in which phosphatidyl glycerol (PG) was present in the
amniotic fluid, in the different White classes.
White class AB
White class B-D
White class F
Number of
patients
21
12
3
Amniocentesis
(weeks)
36.4 ± 0.8
36.5 ± 1.2
35.3 ± 2.3
Delivery
(weeks)
39.3 ± 0.7
38.6 ±1.0
36.0 ± 2.8
Birth Weight
(grams)
3557 ± 145
3448 ± 188
2595 ± 1160
C-peptide
(nmol/1)
0.43 ± 0.04
0.51 ± 0.08
0.32 ±0.1
PG
Present
9/21
6/12
0/3
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birth wei^it of the infants (r = 0.50: significantly hinter than that for uon<Uahetic
p<OOl) (Fig. 1). The C-peptide concentrations pregaancies(OJ8±0.02nniol/l) [17].
cud not differ, on the average, between patients The C-peptide level in ainuiotie fluid in the present
m whom phoshatidyl giycerol was present in study did not discriminate between the presence
the amnioGc fluid (n = 15: 0.56 ± 0.06 nrnol/1) or absence of phosphatidyl glyceroL This observa-
and those in whom it was absent (n = 21 ; tion is in accordance with previous findings in dia-
0.43 ± 0.05 nrno!/l). The gestational age at amnio- betic pregnancies in that there was uo correlation
ceotesis did not differ between these two groups, between the C-peptide level and the L/S ratio in
Two cases of minor respiratory disorders (transient the amniotic fluid [21 ], nor between the C-peptide
tacfaypnea, pneuinothorax) occurred in infants of level in cord blood and the occurrence of RDS in
the group in which phosphatidyl glycerol was the newborn infant [19].
present. These infants were delivered by Cesarean The hypothesis that hyperinsulineinia per $e is the
section from women with gestational diabetes at major factor underlying the disturbed surfactant
term after an uncomplicated prenatal course. production in diabetic pregnancy can be dial·
No attempt was made to correlate phosphatidyl lengpd. According to this hypothesis, one media -
glycerol to the neonatal outcome, because of the nism by which insulin exerts its inhibitory influ-
time lag, of more than 2 weeks between amnio- ence on lung maturation could be by decreasing
centesis and delivery in White classes AB and the availability of substrates for surfactant syn-
B— D. thesis. Thus, the breakdown of lung glycogen.
which is the major carbohydrate source for sur-
factant synthesis, could be inhibited by excess
insulin. The marked changes in the concentration
A T\* *4 Discussion
 Of insuijn receptors that occur during development
The main observation in this study was that the of Λβ fetal rat lung [18] suggest the importance of
biochemical maturation of the fetal lung was not another variable that could significan y modulate
disturbed to any appreciable degree by maternal glycogen metabolism in the lung. It can be specu-
diabetes. Phosphatidyl glycerol was present in lated that a delayed disappearance of insulin
40 per cent of the diabetic pregnancies which is a receptors and an increased receptor affinity for
figure that corresponds to our findings in non- insulin in the fetal lung in the offspring of diabetic
diabetic pregnancies at a comparable gestational women could lead to enhanced insulin sensitivity
age (36 weeks) [22] and is also similar to reports and hence, a decrease in glycogenolysis and in
of other investigators [1,3]. surfactant production. Interestingly, monocytes
This apparently normal degree of fetal lung from infants of mothers with gestational diabetes
maturation is probably attributable to the strict have more insulin receptors than normal, and these
control of the diabetic state during the preg- receptors also show an increased affinity for
nancies. Indeed, in these women the achieved insulin [14]. Another possibility that is supported
metabolic control of maternal blood glucose levels by experimental data [4, 5] is that hyperglycemia
approached normal values, however, there was per se could lead to impaired glycogen degradation
evidence of some degree of fetal hyperinsulinemia, and decreased surfactant production.
as assessed by the concentration of C-peptide in In conclusion the present study shows that with
the amniotic fluid. Although the mean value for rigorous metabolic control of the pregnant dia-
this concentration was close to that found previ- betic patient, the presence or absence of phos-
ously for diabetic pregnancies with an uneventful phatidyl glycerol shows no apparent relationship
neonatal outcome (0.51 ± 0.9 rimol/1), it was to the level of C-peptide in amniotic fluid.
Summary
The concentrations of C-peptide and phosphatidyl glycerol diabetic women. Twenty-one patients who were being
in the amniotic fluid were determined in 36 pregnant treated with insulin for gestational diabetes as well
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as 15 patients who were insulin dependent were studied.
All patients were subjected to a program of strict meta-
bolic control, and amniocentesis was performed at gesta-
tional week 36-37. Phosphatidyl glycerol was present in
the amniotic fluid in 15 cases and absent in 21. The mean
concentration of C-peptide did not differ whether phos-
phatidyl glycerol was present or absent. (C-peptide:
0.56 ± 0.06 and 0.43 ± 0.05 nmol/1 respectively). Although
the mean value for amniotic fluid C-peptide in both
groups was close to that in diabetic pregnancies with an
uneventful neonatal outcome, it was significantly higher
than that in non-diabetic pregnancies, indicating minor
fetal hyperinsulinemia. The level of C-peptide in the
amniotic fluid showed a correlation to the subsequent
birthweight of the infant (r = 0.50; p < 0.01). It is con-
cluded that with rigorous metabolic control of the preg-
nant diabetic patient, the presence or absence of phos-
phatidyl glycerol, as an index of fetal lung maturity, is
apparently not related to the level of C-peptide in the
amniotic fluid.
Key words: Amniotic fluid, C-peptide, diabetes in pregnancy, phosphatidyl glycerols, prenatal diagnosis.
Zusammenfassung
im FruchtwasserC-Peptid und Phosphatidylglycerol
diabetischer Schwangerer.
Wir bestimmten die Konzentrationen von C-Peptid und
Phosphatidylglycerol im Fruchtwasser bei 36 schwangeren
Diabetikerinnen. Bei 21 Frauen bestand ein Schwanger-
schaftsdiabetes, der mit Insulin eingestellt wurde; 15
Frauen hatten schon vor der Schwangerschaft einen
insulinabhängigen Diabetes. Alle Patientinnen unterlagen
einer strengen Stoffwechselkontrolle. Die Amniozentese
wurde zwischen der 36. und 37. Schwangerschaftswoche
durchgeführt. In 15 Fruchtwasserproben konnte Phos-
phatidylglycerol nachgewiesen werden, bei den übrigen
21 Proben nicht. Die mittlere C-Peptid-Konzentration war
unabhängig von der Anwesenheit von Phosphat idylglyce-
rolkonzentration (0,56 ± 0,06 nmoi/1 bei Phosphatidyl-
glycerolnachweis, 0,43 ± 0,05 nmol/1, wenn kein
Phosphatidylglycerol nachweisbar war). Wenn auch die
mittlere C-Peptidkonzentration im Fruchtwasser in
beiden Gruppen vergleichbar war mit Werten bei diabeti-
schen Schwangeren, deren Neugeborene keine neonatalen
Komplikationen zeigten, so war sie doch signifikant höher
als die Konzentration bei nicht-diabetischen Schwangeren,
was wir als Hinweise für einen fetalen Hyperinsulinismus
werteten. Der Gehalt an C-Peptid im Fruchtwasser korre-
lierte mit dem tatsächlichen Geburtsgewicht des Kindes
(r = 0,50; p < 0,01). Wir glauben, daß bei strenger Stoff-
wechselkontrolle einer diabetischen Schwangeren der
Nachweis von Phosphatidylglycerol als Index der fetalen
Lungenreife keinen Zusammenhang mit dem C-Peptid-
Spiegel im Fruchtwasser aufweist.
Schlüsselwörter: C-Peptid, Diabetes und Schwangerschaft, Fruchtwasser, Phosphatidylglycerol, pränatale Diagnose.
Resume
Peptide-C et phosphatidyl glycerol dans le liquide amnio-
tique au cours de la grossesse des diabetiques
On a determine les concentrations de peptide-C et de
phosphatidyl glycerol dans le liquide amniotique de
36 femmes enceintes diabetiques. 21 femmes etaient
en cours de traitement par insuline pour un diabete
gestationnel et 15 etaient insulinodependantes. Toutes
ces patientes etaient soumises ä un programme de strict
contröle metabolique et une amniocentese a ete realisee
au cours de la 36-37eme semaine gestationnelle. II y
avait du phosphatidyl glycerol dans le liquide amniotique
dans 15 cas et pas dans 21. La concentration moyenne
de peptide-C n'etait pas differente qu'il y ait ou non
du phosphatidyl glycerol (respectivement, peptide-C
= 0,56 ± 0,06 et 0,43 ± 0,05 nmol/1). Bien que la valeur
moyenne de peptide-C dans le liquide amniotique ne fit
appel dans les 2 groupes qu'aux grossesses diabetiques
avec un devenir neonatal sans probleme, cette valeur
n'etait significativement plus elevee que dans les grossesses
chez les non-diabetiques, ce qui indique une hyper-
insulinemie foetale minime. Le taux de peptide-C dans le
liquide amniotique a montre une correlation avec le poids
de naissance ulterieur de l'enfant (r = 0,50;p < 0,01). Les
auteurs concluent qu'avec un contröle metabolique
rigoureux chez les diabetiques enceintes, la presence ou
l'absence de phosphatidyl glycerol, en tant qu'index de la
maturite pulmonaire foetale, n'est apparemment pas en
correlation avec le taux de peptide-C du liquide amnio-
tique.
Mots-cles: Diabete gravidique, diagnostic prenatal, liquide amniotique, phosphatidyl glycerol, peptide-C.
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